Direct comparison
510(k) vs PMA: FDA Device Pathways
510(k) clearance compares a device to a predicate; PMA approval requires independent proof of safety and effectiveness. What separates the two pathways.
Ask about 510(k) vs PMA: FDA Device Pathways
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do 510(k), PMA compare side by side?
The table below compares 510(k), PMA across 8 procurement-relevant dimensions, from outcome terminology through typical fda review pace.
Side-by-side comparison
| Dimension | 510(k) | PMA |
|---|---|---|
| Outcome terminology | Device is "cleared" | Device is "approved" |
| Review standard | Comparative — substantial equivalence to a legally marketed predicate device | Independent — the device’s own demonstrated safety and effectiveness, no predicate required |
| Typical device class | Class I or Class II (low to moderate risk) | Class III (high risk; life-supporting, life-sustaining, or substantial-importance devices) |
| Clinical data requirement | Generally not required; FDA may still request it if the predicate comparison can’t resolve a safety question | Generally required — the standard is an independent demonstration of safety and effectiveness |
| Predicate device needed? | Yes — the entire pathway depends on identifying a suitable predicate | No — PMA does not rely on comparison to an existing device |
| Where a novel device with no predicate goes | Not eligible for 510(k) without a predicate | Eligible for PMA, or for De Novo if risk is low-to-moderate and no predicate exists |
| Controls relied on | General controls, plus special controls for Class II | General and special controls are insufficient on their own — that insufficiency is what puts a device in PMA territory |
| Typical FDA review pace | Shorter — FDA’s goal is roughly 90 days for a standard 510(k) | Longer — FDA’s goal is roughly 180 days, often more in practice given clinical-data review |
Common questions
Common questions about 510(k) vs PMA
Is "FDA cleared" the same as "FDA approved"?
+
No, and the distinction is FDA’s own deliberate word choice. "Cleared" describes a 510(k) outcome, based on substantial equivalence to a predicate device. "Approved" describes a PMA outcome, based on independent proof of the device’s own safety and effectiveness. Using them interchangeably in a manuscript, consent document, or grant proposal is a factual error a careful reviewer will flag.
How do I know if my device needs a 510(k) or a PMA?
+
It depends primarily on device classification and predicate availability. Class I and most Class II devices with an identifiable predicate go through 510(k). Class III devices, or any device where general and special controls can’t provide reasonable assurance of safety, require PMA. A device with no predicate at all but low-to-moderate risk may instead be eligible for the De Novo pathway.
Does a 510(k) clearance ever require clinical trial data?
+
It's not the default, but FDA can and does request clinical data for a 510(k) submission when the comparison to a predicate device alone doesn't resolve a safety or effectiveness question — particularly for devices with new technological characteristics.
What is the De Novo pathway, and how does it relate to 510(k) and PMA?
+
De Novo is a third pathway for novel, low-to-moderate-risk devices that have no legally marketed predicate to compare against — which rules out 510(k) — but that don't warrant the full rigor of PMA given their risk profile. A successful De Novo authorization can itself become a predicate for future 510(k) submissions.
Which pathway applies to in vitro diagnostic (IVD) devices?
+
IVDs are regulated as devices and can fall under 510(k), PMA, or De Novo depending on their risk classification, following the same substantial-equivalence-versus-independent-evidence logic as any other device type.
